Victoria Socha

DocwireNews

There are few data available on gout in patients with dialysis-dependent end-stage kidney disease. Anthony J. Bleyer, MD, MS, and colleagues conducted a study to examine the epidemiology, risk factors, and cardiovascular outcomes among dialysis-dependent patients with gout. Results of the study were reported during a poster session at NKF SCM22 in a poster titled Risk Factors and Outcomes of Gout in Dialysis Patients from the United States Renal Data System (USRDS).
Using data from the 2017 USRDS, the researchers identified adult patients ≥18 years of age who were Medicare beneficiaries and receiving dialysis. Characteristics and comorbidities were examined from January 1, 2018. Patients were followed from index diagnosis of <a href="https://www.docwirenews.com/abstracts/the-economic-burden-of-uncontrolled-gout-how-controlling-gout-reduces-cost/">gout</a> until December 31, 2018. The study assessed gout diagnoses, all-cause mortality, and a composite outcome of death and hospitalization for myocardial infarction, strike, or congestive heart failure (CHF).
Of 231,841 dialysis patients, 13% (n=31,300) had one or more gout claims following initiation of chronic dialysis. Compared with patients without gout, those with gout were older (mean 66.9 years vs 61.4 years), more often male (62% vs 55%), were hospitalized more often (66% vs 57%), and underwent hemodialysis via central venous catheter more often (13% vs 11%). Length of hospital stays were also more likely to be longer for patients with gout than for patients without gout.
Gout patients had more comorbidities compared with patients without gout: diabetes (64% vs 61%), chronic obstructive pulmonary disease (26% vs 18%), hypertension (84% vs 73%), hyperlipidemia (54% vs 42%), CHF (42% vs 30%), ischemic heart disease (42% vs 29%), and peripheral vascular disease (27% vs 21%).
In adjusted regression analysis, there was a 2-fold increased risk of gout associated with older age (odds ratio [OR], 4.1 for ≥65 years vs &lt;65 years, 95% confidence ratio [CI], 3.0-4.4), Asian race (OR, 2.4, 95% CI, 2.3-2.5) and higher body mass index (OR, 2.1; 95% CI, 2.0-2.2). Patients with gout had 10% higher erythropoietin stimulating requirements and 8% more red blood cell transfusions than patients without gout. Results of multivariable analyses demonstrated 6% higher risk in gout patients for the composite of death and hospitalization for cardiovascular disease (hazard ratio, 1.06; 95% CI, 1.03-1.09) in the year following diagnosis.
In conclusion, the authors said, “Gout prevalence was 13% in this US Medicare dialysis-dependent population. Gout patients had a higher comorbidity burden, anemia management challenges, and a higher risk for hospitalization/mortality. Further study is needed to assess whether improved gout recognition/management may improve outcomes among dialysis-dependent patients with gout.”
Source: Bleyer AJ, Zhang Y, Ksirasgar O, Marder B, LaMoreaux B. Risk factors and outcomes of gout in dialysis patients from the United States Renal Data System (USRDS). Abstract of a poster (Poster #206) presented at the National Kidney Foundation 2022 Spring Clinical Meetings, Boston, Massachusetts, April 6-10, 2022.

Emily Menendez

KEYNOTE-177 5-Year Follow-Up Shows Durability of Pembrolizumab for mCRC

Colorectal Cancer

Laura Litwin

Can Epigenetics Determine the Best Diet for Lung Health?

Lung Cancer

Rob Dillard

Changes in Maximum Daily Atrial Fibrillation Duration Linked With Poor Outcomes in Patients With Cardiac Implantable Electronic Devices

AHA 2024

Latest News

Risk Factors and Outcomes in Dialysis Patients with Gout

National Kidney Foundation 2022

There are few data available on gout in patients with dialysis-dependent end-stage kidney disease. Anthony J. Bleyer, MD, MS, and colleagues conducted a study to examine the ...

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe